{"name":"Kyowa Kirin Co., Ltd.","slug":"kyowa-kirin-co-ltd","ticker":"","exchange":"","domain":"kyowakirin.com","description":"","hq":"Otemachi Financial City Grand Cube","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1981-01-01","label":"Mitozytrex first approved","drug":"Mitozytrex","drugSlug":"mitomycin","type":"approval","sentiment":"positive"},{"date":"2026-07-19","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-19","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-02","label":"Mitozytrex patent expiry (Compound)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-02-01","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-05-21","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Formulation)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"},{"date":"2031-01-20","label":"Mitozytrex patent expiry (Method of Use)","drug":"Mitozytrex","drugSlug":"mitomycin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"KHK4827-Active","genericName":"KHK4827-Active","slug":"khk4827-active","indication":"Other","status":"marketed"},{"name":"KHK4577","genericName":"KHK4577","slug":"khk4577","indication":"Other","status":"phase_2"},{"name":"KRN23","genericName":"KRN23","slug":"krn23","indication":"X-linked hypophosphatemia (XLH) in children and adults","status":"marketed"},{"name":"KRN321","genericName":"KRN321","slug":"krn321","indication":"Other","status":"phase_2"},{"name":"KHK6640","genericName":"KHK6640","slug":"khk6640","indication":"Other","status":"phase_1"},{"name":"KK2845_1","genericName":"KK2845_1","slug":"kk2845-1","indication":"Other","status":"phase_1"},{"name":"KK2845_3","genericName":"KK2845_3","slug":"kk2845-3","indication":"Other","status":"phase_1"},{"name":"KK2845_6","genericName":"KK2845_6","slug":"kk2845-6","indication":"Other","status":"phase_1"},{"name":"KW-6356 Middle Dose","genericName":"KW-6356 Middle Dose","slug":"kw-6356-middle-dose","indication":"Other","status":"phase_1"},{"name":"KW-6356 X Dose","genericName":"KW-6356 X Dose","slug":"kw-6356-x-dose","indication":"Other","status":"phase_1"},{"name":"KW-6500","genericName":"KW-6500","slug":"kw-6500","indication":"Growth hormone deficiency in adults","status":"phase_3"},{"name":"saxaglipitin","genericName":"saxaglipitin","slug":"saxaglipitin","indication":"Other","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"KHK4827","genericName":"KHK4827","slug":"khk4827","indication":"Thromboembolism prevention (in development)","status":"phase_3"},{"name":"KHK7791","genericName":"KHK7791","slug":"khk7791","indication":"Thrombotic disorders and stroke prevention (Phase 3 development)","status":"phase_3"},{"name":"Plasma-derived antithrombin","genericName":"Plasma-derived antithrombin","slug":"plasma-derived-antithrombin","indication":"Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery","status":"phase_3"},{"name":"KHK7580","genericName":"KHK7580","slug":"khk7580","indication":"Thromboembolism prevention","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"EN3267","genericName":"EN3267","slug":"en3267","indication":"Immunoglobulin A nephropathy (IgAN)","status":"phase_3"},{"name":"KK8398","genericName":"KK8398","slug":"kk8398","indication":"Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Mitozytrex","genericName":"MITOMYCIN","slug":"mitomycin","indication":"Disseminated adenocarcinoma of the stomach or pancreas","status":"marketed"},{"name":"KW-2246","genericName":"KW-2246","slug":"kw-2246","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"KHK4083","genericName":"KHK4083","slug":"khk4083","indication":"Treatment of type 2 diabetes","status":"phase_2"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"KW-2246 (fentanyl citrate)","genericName":"KW-2246 (fentanyl citrate)","slug":"kw-2246-fentanyl-citrate","indication":"Moderate to severe pain (specific indication under investigation in phase 3)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"OPC-262","genericName":"OPC-262","slug":"opc-262","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"KHK4827-Active","genericName":"KHK4827-Active","slug":"khk4827-active","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EN3267","genericName":"EN3267","slug":"en3267","phase":"phase_3","mechanism":"EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.","indications":["Immunoglobulin A nephropathy (IgAN)"],"catalyst":""},{"name":"KHK4577","genericName":"KHK4577","slug":"khk4577","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KHK4827","genericName":"KHK4827","slug":"khk4827","phase":"phase_3","mechanism":"KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.","indications":["Thromboembolism prevention (in development)"],"catalyst":""},{"name":"KHK7791","genericName":"KHK7791","slug":"khk7791","phase":"phase_3","mechanism":"KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk.","indications":["Thrombotic disorders and stroke prevention (Phase 3 development)"],"catalyst":""},{"name":"KK8398","genericName":"KK8398","slug":"kk8398","phase":"phase_3","mechanism":"KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.","indications":["Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"KRN23","genericName":"KRN23","slug":"krn23","phase":"marketed","mechanism":"KRN23 is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23), restoring phosphate reabsorption and vitamin D metabolism in patients with X-linked hypophosphatemia.","indications":["X-linked hypophosphatemia (XLH) in children and adults"],"catalyst":""},{"name":"KRN321","genericName":"KRN321","slug":"krn321","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mitozytrex","genericName":"MITOMYCIN","slug":"mitomycin","phase":"marketed","mechanism":"Indoleamine 2,3-dioxygenase 1","indications":["Disseminated adenocarcinoma of the stomach or pancreas","Palliative treatment for disseminated adenocarcinoma"],"catalyst":""},{"name":"Plasma-derived antithrombin","genericName":"Plasma-derived antithrombin","slug":"plasma-derived-antithrombin","phase":"phase_3","mechanism":"Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors.","indications":["Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery"],"catalyst":""},{"name":"KHK4083","genericName":"KHK4083","slug":"khk4083","phase":"phase_2","mechanism":"KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"KHK6640","genericName":"KHK6640","slug":"khk6640","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KHK7580","genericName":"KHK7580","slug":"khk7580","phase":"phase_3","mechanism":"KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.","indications":["Thromboembolism prevention","Atrial fibrillation stroke prevention"],"catalyst":""},{"name":"KK2845_1","genericName":"KK2845_1","slug":"kk2845-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KK2845_3","genericName":"KK2845_3","slug":"kk2845-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KK2845_6","genericName":"KK2845_6","slug":"kk2845-6","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-2246","genericName":"KW-2246","slug":"kw-2246","phase":"phase_3","mechanism":"KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"KW-2246 (fentanyl citrate)","genericName":"KW-2246 (fentanyl citrate)","slug":"kw-2246-fentanyl-citrate","phase":"phase_3","mechanism":"KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.","indications":["Moderate to severe pain (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"KW-6356 Middle Dose","genericName":"KW-6356 Middle Dose","slug":"kw-6356-middle-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-6356 X Dose","genericName":"KW-6356 X Dose","slug":"kw-6356-x-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KW-6500","genericName":"KW-6500","slug":"kw-6500","phase":"phase_3","mechanism":"KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors.","indications":["Growth hormone deficiency in adults"],"catalyst":""},{"name":"OPC-262","genericName":"OPC-262","slug":"opc-262","phase":"phase_3","mechanism":"OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"saxaglipitin","genericName":"saxaglipitin","slug":"saxaglipitin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQek9wS2ZnNmZtRDRQQ2tBN0dSTDlGMTVWRkktRndkRlRIX2wtVmFmd3RpaVRYN0ZpRFFlRlpLR0RmbXdOLWFoSndzX1lrc19LbzBZd0NQYXFqbUZIbDZINW1sbFVjSkt6MzFIamp2TUJTVW5IempkQXAzanV2dW95cG0zQTZhMWszTjR2cVExbldVQ3dZNTR2WXZIMkNicVFfMU9TUzJZZFBnV1NLWHNNUkdMbzd6dzljLU9mUHhaMUJmY2Ey?oc=5","date":"2026-04-07","type":"pipeline","source":"AD HOC NEWS","summary":"Kyowa Kirin Co Ltd stock: Why this Japanese pharma gem deserves your attention now - AD HOC NEWS","headline":"Kyowa Kirin Co Ltd stock: Why this Japanese pharma gem deserves your attention now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZGFDeEtITEVMQXV0ZHczcEx1NW4ybWx5X1BLNE1ZaGM1YXZJcjhaVXQ0S0Q1OEhBNW9PVkRkbUlQV3VYeW9ybHlTWnBaN2dKMkVXNF9iUFdzUnphSEJCODZzc2ZzenAzazRTWDdvRWg5OW9jR0FUWDA1WU5VcWxvNEY0N1Z0MjB1RFdrNko2dUplVDhJMHgzRXRPbmtBSmQ0QVJJMTY2cFhMZFNGMno4M2t1WHllRzEtY3FVZU9qSjlvREdjVmJTaEFZRnVYQTVmRWk3Y3FMSVlxM2VQ?oc=5","date":"2026-03-04","type":"pipeline","source":"prnewswire.com","summary":"Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - prnewswire.com","headline":"Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPNTlrMzJLMTUyX3RKRzJWYi1UX1RvSlZ2RUNEd2EtcDJmemhHLUlFZXQxSjcza29rTE9kUFRwRUN2ckdQS0tMcHhfUEN1VDUxeHZMQ1A4NWtqeUYwSFBpM1Y5ZUo3U1NqSk9nM2NtQXBwMDg0R2k3a2U4VTVkSktvR1pxVW8zdS1pQUZ5aExHU3dtY3Y3MTUyVmt2NzVITFBQUktxdHVORlM5WDFTcGZGYkJvM3pNc1ByYTFQT1ZNOUZBYkp6elFBbzNqT3RUQXBNU0FVYWoyemFGRUdUajJjTzlZX2kxX0phc1d2M0xoa1g5TWtvT1N0NVBWY2pZcERNd3N2ck5UV3FWU0MxUWtCbnd3?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire UK","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire UK","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-11","type":"pipeline","source":"simplywall.st","summary":"Kyowa Kirin Co., Ltd. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st","headline":"Kyowa Kirin Co., Ltd. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT1hTVnZreC1XUWg0Z29KdkdXazVHUmEwNFRoaG1KRHZaRFRoMzFIeUVDME5wSzRPV0EzTUMtX0N3NGljQVNmMy1lZEdfSHAwb0Ffd3dGQThwZHJmRnBXQTMtNVFrd1hNM2ZzMG0zY0FFdC1Yai0wal95MWxzVW5idHdKWGhBc01Td0NDN0Rsdm5sR1ZrZkQxMFNtWU1DWWNWVUswU2JlbFB4bURxb0Z6Yw?oc=5","date":"2026-01-07","type":"deal","source":"Bloomberg.com","summary":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal - Bloomberg.com","headline":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdHFCOEd6WUVsdVA0b0NDdEpRTXQzQVpDeV9UbUt2ZmdTM3BBZHNoSkE1RnNYMmVJeWpoUE1LNDZLZW96a0FlRVJ5Z0tUN1o2SFg5UVdIUWFKaEk2WERTRnVSVWxPM0dkSU9QaGQ1em92d24yVWt0MHhVNEN1RzZ5d1dLd1U5eE1uUnlad3hxY1ZJYWM5OHNmdERDRk90b0QwNnZpOXdn?oc=5","date":"2025-12-04","type":"regulatory","source":"San Diego Business Journal","summary":"Kura Oncology Secures FDA Approval of Leukemia Drug - San Diego Business Journal","headline":"Kura Oncology Secures FDA Approval of Leukemia Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1kTXVBODV3SVdGanJXbDRvX0lnWDNXa3pLdlQxQkdkS0NGU2d2ZXg5UTU2eWVvUFFVS1lFSGF1dEtHRTNLWEQ3cEZQbjJGZlFkMEtqNU0xVVduOW9Qb3F3MUlaWQ?oc=5","date":"2025-11-15","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5","date":"2025-11-13","type":"regulatory","source":"Reuters","summary":"US FDA approves Kura-Kyowa's blood cancer therapy - Reuters","headline":"US FDA approves Kura-Kyowa's blood cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNVDJCbkdYbzZhWGVEaHdzVU0zb2dpYWVKQTF6THhXTGFsNm9MbVc3ckhDYzIyd19EdjktajU0WDFlZkZtY0xvcVQ0dk5uRTJRdUpfa3Q3clhOdmhvV3RXOWxkNTFTNkhoZk1iQ2lteWpjS1FkcnpLdV9naEdOSTROMzVTbkphU01ZRkhneFVlTjY5cEVsWFR4aC1qTGxEQXo4OG9NNkxfVm9RQ1RfY19KdG9oOTJZdnRNZkxEM2hHam9QMjJBR1ZXck1sZUhaSk40Qk5Ndg?oc=5","date":"2025-11-03","type":"pipeline","source":"BioSpace","summary":"Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - BioSpace","headline":"Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE43YWZmalNrYmNvemxkU2tUWnVfLUpLdDZ4dG1MMTB3djVVSERoWTJiR3FiYzVDZ0gzdVdTVW9aS0w1eERyWGc5YUZVSm5EdEhMTEN1T0plYVpBc3JlVzVqeWZWa0VHLWMw?oc=5","date":"2025-09-09","type":"trial","source":"Wiley Online Library","summary":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study - Wiley Online Library","headline":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPMS1HMXJOQkZRSFBVaGJxcWJmQVVjM1dadlVnSjAzNTBXdW5Tei1KUFNCNUZMc0NBemFtY1VJdjNzUmlXeGpMbmw0eFJzaGx2MFRkQ2l4RElOUGl2MnBPWFhBc2JSYWRuR244SkpTWF9Tdk13NkZtNGxWWEc4cVFESWxZcElqb0hNMUxjMnQ2RlFYYmNIRTA2R0xKZ0lFOS03NGNsZ092Sk4yc0M3VU5LMExldG1oUmVFRHBBZFY2T0dsajZ1?oc=5","date":"2025-04-11","type":"pipeline","source":"Fierce Pharma","summary":"As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan - Fierce Pharma","headline":"As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxQdmZ1Sm9wNzI4YkFVRWtXQzdrWUt3U0pXUWxNNG1NSWVtX3dwaUlEd0RSelhJX041T2lVS2h5SXhTNENkakZDTzNUM2ZRZ0FXbHN5SC1BVkhoeGYxcWhjRUh6cGN5NUQwbjdvNGNYYmdRckpzU05RZHRhbEhNVENfQjZhaEFJUjg1SGxMZEJqOUZyS01MNG9RVkljYTk5a0hwUUNKY3Rub0RONXIxdEZVTFd0cXNpU3F2amw0MnU5Y2lqVUZHTzJ0aDVSRXo1WnQxckIwS3JnZHNtY2pBNnpyWk5xd0s3WnRBdi15ZnBqZU4zWlQ3U3ZqSjU1ZF9BRnFQZjFJNldwblpRc1ZqQ002WW0wOWg2a18xYkk3Q2JFSlRzYkRRMEN1TFpGUlNQTmt3OUlnRFNjdi1EQVJSTzBvMm5MQVVOaHVjbm9kTEVDUVVTQVhIX0F2cw?oc=5","date":"2024-02-07","type":"deal","source":"GlobeNewswire","summary":"BridgeBio Pharma and Kyowa Kirin Announce Partnership with - GlobeNewswire","headline":"BridgeBio Pharma and Kyowa Kirin Announce Partnership with","sentiment":"neutral"}],"patents":[{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"8186511","type":"Formulation","expiryDate":"2026-07-19","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9205075","type":"Formulation","expiryDate":"2026-07-19","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9539241","type":"Compound","expiryDate":"2028-01-02","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"7806265","type":"Formulation","expiryDate":"2029-02-01","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9649428","type":"Method of Use","expiryDate":"2029-05-21","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"10039832","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9950069","type":"Formulation","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"9040074","type":"Formulation","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"12268745","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]},{"drugName":"Mitozytrex","drugSlug":"mitomycin","patentNumber":"12440568","type":"Method of Use","expiryDate":"2031-01-20","territory":"US","genericFilings":[]}],"drugCount":23,"phaseCounts":{"marketed":3,"phase_3":11,"phase_2":3,"phase_1":6},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}